GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDL Biotech AB (XSAT:IDL) » Definitions » Revenue

IDL Biotech AB (XSAT:IDL) Revenue : kr19.64 Mil (TTM As of Jun. 2021)


View and export this data going back to 2004. Start your Free Trial

What is IDL Biotech AB Revenue?

IDL Biotech AB's revenue for the three months ended in Jun. 2021 was kr6.33 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2021 was kr19.64 Mil. IDL Biotech AB's Revenue per Share for the three months ended in Jun. 2021 was kr0.10. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2021 was kr0.31.

Warning Sign:

IDL Biotech AB revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of IDL Biotech AB was -24.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was -33.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was -15.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was 0.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, IDL Biotech AB's highest 3-Year average Revenue per Share Growth Rate was 21.60% per year. The lowest was -33.70% per year. And the median was 4.95% per year.


IDL Biotech AB Revenue Historical Data

The historical data trend for IDL Biotech AB's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDL Biotech AB Revenue Chart

IDL Biotech AB Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.49 32.31 27.39 28.35 21.75

IDL Biotech AB Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.92 3.04 5.57 4.71 6.33

Competitive Comparison of IDL Biotech AB's Revenue

For the Diagnostics & Research subindustry, IDL Biotech AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDL Biotech AB's Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDL Biotech AB's Revenue distribution charts can be found below:

* The bar in red indicates where IDL Biotech AB's Revenue falls into.



IDL Biotech AB Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was kr19.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IDL Biotech AB  (XSAT:IDL) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


IDL Biotech AB Revenue Related Terms

Thank you for viewing the detailed overview of IDL Biotech AB's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


IDL Biotech AB (XSAT:IDL) Business Description

Traded in Other Exchanges
N/A
Address
Karlsbodavagen 39, Stockholm, SWE
IDL Biotech AB develops, produces and markets In Vitro Diagnostic tests for the health care sector. It offers in vitro diagnostic tests within the clinical areas of oncology and bacteriology. The company's trademark products includes TUBEX, TPS, UBC, MonoTotal and TPAcyk.

IDL Biotech AB (XSAT:IDL) Headlines

No Headlines